Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer

Pharmacogenomics

Volumn 12, Issue 12, 2011, Pages 1681-1693

  Hansen, Torben Frøstrup ^a   Jakobsen, Anders ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

Author keywords

biomarkers; colorectal neoplasms; haplotypes; SNPs; VEGF; VEGF receptors

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ALLELE; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER RISK; COLORECTAL CANCER; ETHNICITY; GENE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; PREDICTIVE VALUE; PROGNOSIS; PROMOTER REGION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VEGF A GENE; VEGFR1 GENE; VEGFR2 GENE;

COLORECTAL NEOPLASMS; HUMANS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 82255193096     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.118     Document Type: Review

References (77)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005). (Pubitemid 40372904)
2. Boyle P, Ferlay J. Mortality and survival in breast and colorectal cancer. Nat. Clin. Pract. Oncol. 2, 424-425 (2005). (Pubitemid 41679088)
3. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9, 653-660 (2003). (Pubitemid 36749213)
4. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 9 (Suppl. 1), 2-10 (2004). (Pubitemid 38747842)
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9, 669-676 (2003). (Pubitemid 36749215)
6. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (London) 109, 227-241 (2005). (Pubitemid 41337127)
7. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611 (2004). (Pubitemid 39099316)
8. Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int. J. Colorectal Dis. 24, 677-685 (2009).
9. Wagner AD, Arnold D, Grothey A, Haerting J, Unverzagt S. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst. Rev. (3), CD005392 (2009).
10. Schneider BP, Radovich M, Miller KD. The role of vascular endothelial growth factor genetic variability in cancer. Clin. Cancer Res. 15, 5297-5302 (2009).
11. Mackay TF, Stone EA, Ayroles JF. The genetics of quantitative traits: challenges and prospects. Nat. Rev. Genet. 10, 565-577 (2009).
12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100, 57-70 (2000). (Pubitemid 30046295)
13. Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82, 4-6 (1990). (Pubitemid 20020880)
14. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 161, 851-858 (1989). (Pubitemid 19162712)
15. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 15, 102-111 (2005). (Pubitemid 40127638)
16. Teicher BA. A systems approach to cancer therapy. (Antioncogenics+ standard cytotoxics: mechanism (s) of interaction). Cancer Metastasis Rev. 15, 247-272 (1996).
17. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001). (Pubitemid 32937367)
18. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62 (2005). (Pubitemid 40093472)
19. Gerber HP, McMurtrey A, Kowalski J et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3́-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336-30343 (1998). (Pubitemid 28545503)
20. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87, 3336-3343 (1996). (Pubitemid 26115364)
21. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 20, 4368-4380 (2002). (Pubitemid 35266299)
22. Vincenti V, Cassano C, Rocchi M, Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 93, 1493-1495 (1996). (Pubitemid 26115412)
23. Wei MH, Popescu NC, Lerman MI, MerrillMJ, Zimonjic DB. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum. Genet. 97, 794-797 (1996). (Pubitemid 26150850)
24. Garcia-Closas M, Malats N, Real FX et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet. 3 (2), e29 (2007).
25. Fan F, Wey JS, McCarty MF et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 24, 2647-2653 (2005). (Pubitemid 40593092)
26. Park JE, Chen HH, Winer J, Houck KA, Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, invitro and invivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem. 269, 25646-25654 (1994).
27. Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES. High-resolution haplotype structure in the human genome. Nat. Genet. 29, 229-232 (2001). (Pubitemid 32952664)
28. Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica V, Hutchinson IV. Novel polymorphisms in the promoter and 5́UTR regions of the human vascular endothelial growth factor gene. Hum. Immunol. 60, 1245-1249 (1999). (Pubitemid 30017507)
29. Menendez D, Krysiak O, Inga A, Krysiak B, Resnick MA, Schonfelder G. A SNP in the flt-1 promoter integrates the VEGF system into the p53 transcriptional network. Proc. Natl Acad. Sci. USA. 103, 1406-1411 (2006). (Pubitemid 43191178)
30. Fuh G, Li B, Crowley C, Cunningham B, Wells JA. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J. Biol. Chem. 273, 11197-11204 (1998). (Pubitemid 28204970)
31. Tao Q, Backer MV, Backer JM, Terman BI. Kinase insert domain receptor (KDR) extracellular immunoglobulin-like domains 4-7 contain structural features that block receptor dimerization and vascular endothelial growth factor-induced signaling. J. Biol. Chem. 276, 21916-21923 (2001).
32. Xu B, Feng NH, Tong N et al. VEGF-460C〉T polymorphism and cancer risk: a meta-analysis. Med. Oncol. 27, 1031-1036 (2010).
33. Maltese P, Canestrari E, Ruzzo A et al. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. Int. J. Colorectal Dis. 24, 165-170 (2009).
34. Cacev T, Loncar B, Seiwerth S, Spaventi S, Kapitanovic S. Vascular endothelial growth factor polymorphisms-1154 G/A and-460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol. 27, 569-574 (2008).
35. Dassoulas K, Gazouli M, Rizos S et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol. Carcinog. 48, 563-569 (2009).
36. Cao C, Fang JJ, Ying T et al. Vascular endothelial growth factor +936C/T and +405G/C polymorphisms and cancer risk: a meta-analysis. Arch. Med Res. 41, 548-557 (2010).
37. Hofmann G, Langsenlehner U, Renner W et al. Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J. Cancer Res. Clin. Oncol. 134, 591-595 (2007).
38. Chae YS, Kim JG, Sohn SK et al. Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer. J. Korean Med. Sci. 23, 421-427 (2008).
39. Wu GY, Hasenberg T, Magdeburg R, Bonninghoff R, Sturm JW, Keese M. Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J. Surg. 33, 124-129 (2009).
40. Bae SJ, Kim JW, Kang H, Hwang SG, Oh D, Kim NK. Gender-specific association between polymorphism of vascular endothelial growth factor (VEGF 936 C〉T) gene and colon cancer in Korea. Anticancer Res. 28, 1271-1276 (2008). (Pubitemid 351578865)
41. Jain L, Vargo CA, Danesi R et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol. Cancer Ther. 8, 2496-2508 (2009).
42. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat. Rev. Genet. 10, 353-358 (2009.
43. Eroglu A, Gulec S, Kurtman C, Cam R, Akar N. Vascular endothelial growth factor 936 C/T polymorphism in cancer patients. Ann. Oncol. 17, 1467-1468 (2006). (Pubitemid 44400390)
44. Park HM, Hong SH, Kim JW et al. Gender-specific association of the VEGF-2578C 〉 A polymorphism in Korean patients with colon cancer. Anticancer Res. 27, 2535-2539 (2007).
45. Awata T, Inoue K, Kurihara S et al. A common polymorphism in the 5́-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 51, 1635-1639 (2002). (Pubitemid 34826636)
46. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 37, 443-448 (2000). (Pubitemid 32037619)
47. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 63, 812-816 (2003). (Pubitemid 36231981)
48. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12, 1232-1235 (2000). (Pubitemid 30611801)
49. Yamamori M, Taniguchi M, Maeda S et al. VEGF T-1498C polymorphism, a predictive marker of differentiation of colorectal adenocarcinomas in Japanese. Int. J. Med. Sci. 5, 80-86 (2008). (Pubitemid 351871010)
50. Uthoff SM, Duchrow M, Schmidt MH et al. VEGF isoforms and mutations in human colorectal cancer. Int. J. Cancer 101, 32-36 (2002). (Pubitemid 34832994)
51. Yamamori M, Sakaeda T, Nakamura T et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem. Biophys. Res. Commun. 325, 144-150 (2004). (Pubitemid 39441172)
52. Hansen TF, Spindler KL, Lorentzen KA et al. The importance of-460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. J. Cancer Res. Clin. Oncol. 136, 751-758 (2009).
53. Hansen TF, Sorensen FB, Spindler KL et al. Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. Virchows Arch. 456, 251-260 (2010).
54. Des GG, Uzzan B, Nicolas P et al. Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br. J. Cancer 94, 1823-1832 (2006). (Pubitemid 43882572)
55. Kim JG, Chae YS, Sohn SK et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin. Cancer Res. 14, 62-66 (2008).
56. Hansen TF, Spindler KL, Andersen RF et al. The prognostic value of haplotypes in the vascular endothelial growth factor A gene in colorectal cancer. Cancers 2, 1405-1418 (2010).
57. Lurje G, Zhang W, Schultheis AM et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann. Oncol. 19, 1734-1741 (2008).
58. Lurje G, Hendifar AE, Schultheis AM et al. Polymorphisms in interleukin1 beta and interleukin1 receptor antagonist associated with tumor recurrence in stageII colon cancer. Pharmacogenet. Genomics 19, 95-102 (2009).
59. Jain L, Sissung TM, Danesi R et al. Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. J. Exp. Clin. Cancer Res. 29, 95 (2010).
60. Hansen TF, Garm-Spindler KL, AndersenRF, Lindebjerg J, Brandslund I, Jakobsen A. The predictive value of genetic variations in the vascular endothelial growth factorA gene in metastatic colorectal cancer. PharmacogenomicsJ. 11, 53-60 (2010).
61. Formica V, Palmirotta R, Del MG et al. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int. J. Colorectal Dis. 26, 143-151 (2011).
62. Zhang W, Gordon M, Press OA et al. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet. Genomics 16, 475-483 (2006). (Pubitemid 43922345)
63. Schneider BP, Wang M, Radovich M et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 26, 4672-4678 (2008).
64. Schultheis AM, Lurje G, Rhodes KE et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 14, 7554-7563 (2008).
65. Hansen TF, Christensen RD, Andersen RF, Spindler KL, Johnsson A, Jakobsen A. The predictive value of single nucleotide polymorphisms in the vascular endothelial growth factor system in patients with metastatic colorectal cancer treated with bevacizumab plus chemotherapy as first-line treatment. Results of the PhaseIII ACT trial NCT00598156 translational study. Presented at: 2011 ASCO Annual Meeting. Chicago, IL, USA, 3-7June 2011
66. Lambrechts D, Delmar P, Buysschaert I. VEGFR-1 polymorphisms as potential predictors of clinical outcome in bevacizumab-treated patients with metastatic pancreatic cancer. Presented at: Joint ECCO 15-34th ESMO Multidisciplinary Congress. Berlin, Germany, 20-24September 2009
67. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J. Clin. Oncol. 27, 4027-4034 (2009).
68. Muniz JJ, Izidoro-Toledo TC, Metzger IF, Sandrim VC, Tanus-Santos JE. Interethnic differences in the distribution of clinically relevant vascular endothelial growth factor genetic polymorphisms. DNA Cell Biol. 28, 567-572 (2009).
69. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am. J. Epidemiol. 163, 300-309 (2006). (Pubitemid 43238423)
70. Schneider BP, Skaar TC, Sledge GW, Badve S, Li L, Flockhart DA. Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes. Breast Cancer Res. Treat. 96, 209-215 (2006).
71. McWhinney SR, Mcleod HL. Using germline genotype in cancer pharmacogenetic studies. Pharmacogenomics 10, 489-493 (2009).
72. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J. Natl Cancer Inst. 101, 1446-1452 (2009).
73. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989 (2001). (Pubitemid 32289743)
74. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 76, 449-462 (2005). (Pubitemid 40250525)
75. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, De GA. Integrating biomarkers in clinical trials. Expert Rev. Mol. Diagn 11, 171-182 (2011).
76. Kang MJ, Jung SA, Jung JM et al. Associations between single nucleotide polymorphisms of MMP2, VEGF, and HIF1A genes and the risk of developing colorectal cancer. Anticancer Res. 31, 575-584 (2011).
77. Vidaurreta M, Sanchez-Munoz R, Veganzones S et al. Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer. Rev. Esp. Enferm. Dig. 102, 20-31 (2010).